Deal Tracker · Countries
United States pharma licensing deals
9 licensing deals involving United States tracked by EPT (2021–2026). Most active: Gilead Sciences, Hikma Pharmaceuticals, Bio-Thera Solutions & Dr. Reddy's Laboratories. Latest: Gilead Sciences → Dr. Reddy's Laboratories (Licensing, 16 Nov 2026).
- EPT has tracked 9 United States pharma licensing deals (2021–2026), 7 of them announced in 2026.
- The countries that appear most often are Saudi Arabia (2), China (1), Egypt (1) & India (1).
- Values were disclosed for 1 of 9 deals, totalling $259m; the largest is Ocugen → Roots Pharmaceutical ($259m, 14 Oct 2026).
- The most active companies: Gilead Sciences (3) & Hikma Pharmaceuticals (2).
- Gilead Sciences → Dr. Reddy's LaboratoriesLicensing · Global (LMICs) · Royalty-free · 16 Nov 2026
- Gilead Sciences → Ferozsons LaboratoriesLicensing · Global (LMICs) · Royalty-free · 16 Nov 2026
- Gilead Sciences → Eva PharmaLicensing · Global (LMICs) · Royalty-free · 16 Nov 2026
- Ocugen → Roots PharmaceuticalLicensing · MENA · $259m · 14 Oct 2026
- OMEZA → Hikma PharmaceuticalsLicensing · MENA · Undisclosed · 21 Sept 2026
- MSD → 7 generic manufacturersLicensing · Global (LMICs) · See terms · 5 Aug 2026
- Genetix Biotherapeutics → SPIMACOLicensing · MENA · Undisclosed · 23 Jun 2026
- Kashiv BioSciences → MS PharmaLicensing · MENA · Undisclosed · 8 May 2025
- Bio-Thera Solutions → Hikma PharmaceuticalsLicensing · Undisclosed · 27 Aug 2021
Most active companies
Gilead Sciences (3) · Hikma Pharmaceuticals (2)
Largest disclosed deals
- Ocugen → Roots Pharmaceutical · $259m · Licensing · 14 Oct 2026
Questions
- How many United States pharma licensing deals has EPT tracked?
- 9 as of 16 Nov 2026, covering 2021–2026; 7 were announced in 2026. The most recent is Gilead Sciences → Dr. Reddy's Laboratories (Licensing, 16 Nov 2026).
- Which companies are most active in United States pharma licensing deals?
- Gilead Sciences (3 deals), Hikma Pharmaceuticals (2 deals).
- What is the largest disclosed United States pharma licensing deal?
- Ocugen → Roots Pharmaceutical: $259m (Licensing, 14 Oct 2026). Values are as announced by the parties.
Browse deals
By region
GCC (83) · MENA (66) · Africa (17) · Latin America (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)
By country
Saudi Arabia (69) · UAE (61) · China (31) · Egypt (27) · United States (26) · Oman (20) · India (19) · Switzerland (18) · Jordan (14) · South Korea (14) · Kazakhstan (13) · Algeria (12) · Türkiye (12) · United Kingdom (11) · Brazil (10) · Kuwait (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Spain (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Taiwan (4) · Tunisia (4) · Canada (3) · Chile (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)
By deal type
Licensing (56) · Distribution (41) · Technology transfer / Localization (39) · Partnership / Collaboration (35) · M&A / Acquisition (21) · Equity / Investment (18) · Joint venture (11) · Supply / Manufacturing (10)
Popular searches
MENA pharma licensing deals (25) · Saudi Arabia pharma licensing deals (24) · GCC pharma distribution deals (21) · GCC pharma partnerships (19) · China pharma licensing deals (17) · UAE pharma distribution deals (17) · GCC pharma localization & tech-transfer deals (15) · Saudi Arabia pharma distribution deals (14) · UAE pharma partnerships (13) · UAE pharma licensing deals (12) · Global (LMICs) pharma licensing deals (11) · India pharma licensing deals (11) · GCC pharma licensing deals (10) · MENA pharma partnerships (10) · Saudi Arabia pharma localization & tech-transfer deals (10) · MENA pharma localization & tech-transfer deals (9) · Egypt pharma localization & tech-transfer deals (8) · Saudi Arabia pharma partnerships (8) · CIS & Central Asia pharma localization & tech-transfer deals (7) · Kazakhstan pharma localization & tech-transfer deals (7) · MENA pharma distribution deals (7) · MENA pharma M&A deals (7) · United States pharma distribution deals (7)
By company
ADCAN Pharma (13) · Mubadala Bio (8) · Jamjoom Pharma (7) · SPIMACO (7) · Arcera Life Sciences (6) · Hikma Pharmaceuticals (6) · Bio-Thera Solutions (6) · Avalon Pharma (5) · Tabuk Pharmaceuticals (5) · Local Content and Government Procurement Authority (5) · Kazakhstan Ministry of Health (5) · Eva Pharma (4) · Sandoz (4) · Department of Health – Abu Dhabi (4) · Biocon (4) · Groupe Saidal (4) · Gilead Sciences (3) · Dr. Reddy's Laboratories (3) · Emirates Drug Establishment (3) · Novo Nordisk (3) · Khazaen Economic City (3) · Galenicum (3) · Roche (3) · Laprophan (3) · Sanofi (3) · Gen İlaç (3) · Taiba Healthcare (3) · Dar Al Dawa (3) · Lifera (3) · Celltrion (2) · Viatris (2) · Rem3dy Health (2) · AMA Medical Manufacturing (2) · Afreximbank (2) · M42 (2) · Abbott (2) · DKSH (2) · Adalvo (2) · Rameda (2) · Menarini (2) · Korea United Pharm (2) · Samsung Bioepis (2) · AstraZeneca (2) · MS Pharma (2) · LifePharma (2) · Duopharma Biotech (2) · JCR Pharmaceuticals (2) · Philex Pharmaceuticals (2) · Lotus Pharmaceutical (2) · Elpen (2) · Dhofar Pharmaceutical Industries (2) · Accord Healthcare (2) · CCL Pharmaceuticals (2) · Abdi İbrahim (2) · Nordic Pharma (2) · UNIMED Laboratories (2) · Minapharm (2) · SaudiVax (2) · Faes Farma (2) · AJA Pharma (2) · VACSERA (2) · Bayer (2) · Shanghai Henlius Biotech (2) · Julphar (2)
By therapeutic area
Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)